Composite and surrogate outcomes in randomised controlled trials
- 12 April 2007
- Vol. 334 (7597) , 756-757
- https://doi.org/10.1136/bmj.39176.461227.80
Abstract
Composite end points may mislead—and regulators allow it to happenKeywords
This publication has 6 references indexed in Scilit:
- Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trialsBMJ, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Validity of composite end points in clinical trialsBMJ, 2005
- Composite Outcomes in Randomized TrialsJAMA, 2003
- End-Point Interpretation in Clinical Trials: The Case for DisciplineControlled Clinical Trials, 1999